Xempritolimod

昔瑞托莫德

Report date: 2025/06/24 16:51:52

Base Information

Drug NameXempritolimod
Drug Alias NameAdvanced entolimodKorea Medical Radiation Countermeasure 011KMRC-011KMRC011CNT-101 +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionNuclear factor NF-kappa-B complex modulatorsToll like receptor 5 agonistsApoptosis inhibitors
TargetsNuclear factor NF-kappa-B complexToll like receptor 5
Therapy Area/IndicationsAcute Radiation SyndromeGraft vs Host DiseaseStomatitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKorea Institute Of Industrial Technology
China Registration ClassN/A

Develop Information

Active CompaniesConnext Co Ltd
Inactive CompaniesIntron Biotechnology Inc
Active IndicationsGraft vs Host DiseaseStomatitisNeoplasms
Inactive IndicationsAcute Radiation Syndrome

Other Information

ATC CodeN/A
Related LinksN/A